• E-mail
• Print
• Comment
• Font Size
• Digg
• del.icio.us
• Discuss article

Patients Say MPM Medical's Regenecare Gel Significantly Reduced the Itching and Pain of Skin Rashes Triggered by Anti-Cancer Drugs

Posted on: Monday, 30 March 2009, 07:50 CDT

IRVING, Texas, March 30 /PRNewswire-FirstCall/ -- Patients undergoing cancer treatment reported that using Regenecare hydrogel significantly reduced the pain and itching associated with the sometimes-severe skin rashes caused by anti-cancer drugs.

Conducted by the Western University of Health Sciences, the study substantiated the findings of nine previous clinical trials recognizing Regenecare for its pain-relieving and wound-healing benefits. Manufactured by MPM Medical, Inc., Regenecare is the only wound and pain management product of its kind on the market.

"Pain management is one of the most-significant issues facing healthcare today," said MPM President Paul Miller. "Many patients stop or forgo treatment because they cannot tolerate the itching and painful side effects often associated with these treatments. Regenecare is a unique hydrogel whose benefits are substantiated by science and validated by patients."

The six-week study followed 13 patients who were taking a class of anti-cancer drugs that, while effective, often produce a severe rash on a patient's face, neck, back and legs. If scratched, these rashes can become infected. Patients reported "significant reduction" of itching when using Regenecare, according to the study.

Researchers credit Regenecare's unparalleled pain relief and wound healing to its formulation of 2% lidocaine (for local pain management), marine collagen (to promote tissue formation), Aloe vera (to enhance circulation and to promote emollient effect) and sodium alginate (to absorb exudates).

"Pain is the leading cause of disability in the United States and is straining our healthcare system," according to the National Pain Care Policy Act of 2008 (H.R. 2994). Among other things, the pending legislation seeks "to improve the assessment, understanding and treatment of pain."

MPM offers Regenecare HA as an over-the-counter version of the prescription Regenecare. Regenecare HA has the same formulation, but it also contains hyaluronic acid, which enhances moisture and healing. Consumers may purchase Regenecare and other MPM products online at www.MPMmedicalinc.com.

About RBC Life SciencesRBC Life Sciences (OTC Bulletin Board: RBCL) develops, manufactures and markets high-quality nutritional supplements and personal care products to a growing population of consumers seeking wellness and a healthy lifestyle. Under its MPM Medical, Inc., brand, RBC Life Sciences also develops and markets to health care professionals in the United States proprietary prescription and nonprescription products for advanced wound care and pain management. All products are tested for quality assurance in-house, and by outside independent laboratories, to comply with regulations in the U.S. and in more than thirty countries in which the products are distributed. For more information, visit the Company's Web site at www.rbclifesciences.com.

The statements above, other than statements of historical fact, may be forward-looking. Actual events will be dependent upon a number of factors and risks including, but not limited to, changes in plans by the Company's management, delays or problems in production, changes in the regulatory process, changes in market trends, and a number of other factors and risks described from time to time in the Company's filings with the Securities and Exchange Commission.

SOURCE RBC Life Sciences

Source: PR Newswire

More News in this Category